Singapore Atrial fibrillation is a type of irregular heartbeat
characterized by rapid and irregular beating. Blood may clot and congest in the
atria at the same time because of insufficient blood received by ventricles.
These clots can enter the circulation and reach the brain, causing stroke. The
transmission of electrical impulses to the lower heart chambers is disrupted in
atrial fibrillation, which causes a rapid, slow, or irregular heartbeat. During
atrial fibrillation, upper chamber and lower chamber of the heart beat
irregularly, chaotically, and out of sync, which causes shortness of breath,
chest pain, weakness, ad lightheadedness or fainting.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝
𝐒𝐚𝐦𝐩𝐥𝐞
𝐑𝐞𝐩𝐨𝐫𝐭
https://www.alliedmarketresearch.com/request-sample/479
Numerous technical improvements in the treatment and
diagnostics of Singapore atrial fibrillation, as well as the rise in prevalence of atrial
fibrillation in the senior population, are major drivers of atrial fibrillation
industry. However, market expansion is hampered by problems, such as strict government
laws, expensive treatment costs for atrial fibrillation, and shortage of
experienced specialists and technicians.
Key players focus on expanding their portfolio by
introducing technologically developed products, which re expected to help
reduce the risk of stroke and atrial fibrillation in patients. For instance, in
April 2021, ArtiCure, Inc., a major pioneer in atrial fibrillation (Afib)
therapy introduced Epi-Sense System, which is approved by the U.S. Food &
Drug Administration (FDA). Epi-Sense System is used to treat patients with
long-standing persistent cardiac arrhythmias or Singapore atrial fibrillation.
However, during the COVID-19 pandemic lockdown, various
manufacturers in the Singapore atrial fibrillation market had to stop their business in
countries, such as China, the U.S., and India, which negatively affected the
atrial fibrillation market growth. This break directly impacted the sales and
decline in atrial fibrillation market share. In addition, lack of manpower and
raw materials also constricted supply of equipment of atrial fibrillation,
which negatively influenced the growth of the market. However, reopening of
production facilities and introduction of vaccines for COVID-19 are anticipated
to lead to re-opening of atrial fibrillation companies.
𝗚𝗲𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱
𝐑𝐞𝐩𝐨𝐫𝐭
https://www.alliedmarketresearch.com/atrial-fibrillation-market
0 Comments